XSWX:LONN (Switzerland)
Business Description
Lonza Group Ltd
Muenchensteinerstrasse 38, Basel, CHE, CH-4002
Compare
Compare
Traded in other countries / regions
LO3.Germany
•
LONN.Mexico
•
O6Z.Singapore
•
LONN.Switzerland
•
0QNO.UK
•
LZAGF.USA
Description
Lonza Group is a contract development and manufacturing organization, or CDMO. It operates under four segments: small molecules, biologics, cell & gene, and capsules & health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing services throughout the entire lifecycle of a product from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.01 | |||||
| Equity-to-Asset | 0.6 | |||||
| Debt-to-Equity | 0.24 | |||||
| Debt-to-EBITDA | 2.13 | |||||
| Interest Coverage | 15.82 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 5.19 | |||||
| Beneish M-Score | -1.63 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -0.7 | |||||
| 3-Year EBITDA Growth Rate | -1.6 | |||||
| 3-Year EPS without NRI Growth Rate | 1.1 | |||||
| 3-Year Book Growth Rate | 16.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 17.46 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 12.43 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 50.74 | |||||
| 9-Day RSI | 52.9 | |||||
| 14-Day RSI | 53.68 | |||||
| 6-1 Month Momentum % | -9.61 | |||||
| 12-1 Month Momentum % | -23.13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.17 | |||||
| Quick Ratio | 2.17 | |||||
| Cash Ratio | 0.93 | |||||
| Days Inventory | 134.2 | |||||
| Days Sales Outstanding | 51.26 | |||||
| Days Payable | 40.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.53 | |||||
| Dividend Payout Ratio | 0.25 | |||||
| 3-Year Dividend Growth Rate | 2.9 | |||||
| Forward Dividend Yield % | 0.53 | |||||
| 5-Year Yield-on-Cost % | 0.53 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 38.69 | |||||
| Operating Margin % | 19.75 | |||||
| Net Margin % | 53.29 | |||||
| ROE % | 34.6 | |||||
| ROA % | 19.34 | |||||
| ROIC % | 7.18 | |||||
| ROC (Joel Greenblatt) % | 39.04 | |||||
| ROCE % | 8.43 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 13.62 | |||||
| Forward PE Ratio | 38.31 | |||||
| PE Ratio without NRI | 46.66 | |||||
| Shiller PE Ratio | 58.54 | |||||
| Price-to-Owner-Earnings | 14.85 | |||||
| PEG Ratio | 7.07 | |||||
| PS Ratio | 7.26 | |||||
| PB Ratio | 4.23 | |||||
| Price-to-Tangible-Book | 4.23 | |||||
| Price-to-Operating-Cash-Flow | 43.85 | |||||
| EV-to-EBIT | 37.37 | |||||
| EV-to-Forward-EBIT | 32.66 | |||||
| EV-to-EBITDA | 37.37 | |||||
| EV-to-Forward-EBITDA | 22.19 | |||||
| EV-to-Revenue | 7.23 | |||||
| EV-to-Forward-Revenue | 6.86 | |||||
| EV-to-FCF | -60.56 | |||||
| Price-to-Projected-FCF | 4.05 | |||||
| Price-to-Median-PS-Value | 3.07 | |||||
| Price-to-Peter-Lynch-Fair-Value | 9.59 | |||||
| Price-to-Graham-Number | 2.96 | |||||
| Earnings Yield (Greenblatt) % | 2.68 | |||||
| Forward Rate of Return (Yacktman) % | 7.22 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil CHF) | 5,849 | ||
| EPS (TTM) (CHF) | 41.85 | ||
| Beta | 0.86 | ||
| Volatility % | 33.84 | ||
| 14-Day RSI | 53.68 | ||
| 14-Day ATR (CHF) | 16.62041 | ||
| 20-Day SMA (CHF) | 566.44 | ||
| 12-1 Month Momentum % | -23.13 | ||
| 52-Week Range (CHF) | 475.9 - 785.4 | ||
| Shares Outstanding (Mil) | 74.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lonza Group Ltd Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||